Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) Director Andreas Rummelt unloaded 5,052 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $170.53, for a total transaction of $861,517.56. Following the transaction, the director now directly owns 12,786 shares in the company, valued at approximately $2,180,397. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $183.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.80% on Wednesday, hitting $169.17. 837,764 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a one year low of $100.89 and a one year high of $185.43. The stock has a 50-day moving average of $163. and a 200-day moving average of $163.2. The company has a market cap of $33.464 billion and a P/E ratio of 86.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 24th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.